References - Therapeutic Strategies in Cancer Biology and Pathology - page 212

Goc, A., Abdalla, M., Al-Azayzih, A., Somanath, P.R., 2012. Rac1 activation driven by 14-3-3
zeta dimerization promotes prostate cancer cell-matrix interactions, motility and transen-
dothelial migration. PLoS ONE 7, e40594.
Goldberg, S.F., Miele, M.E., Hatta, N., Takata, M., Paquette-Straub, C., Freedman, L.P., et al.,
2003. Melanoma metastasis suppression by Chromosome 6. Evidence for a pathway reg-
ulated by CRSP3 and TXNIP. Cancer Res. 63, 432-440.
Goldstein, I., Rotter, V., 2012. Regulation of lipid metabolism byp53 - fighting two villains
with one sword. Trends Endocrinol. Metab. 23, 567-575.
Gomez-Cabello, D., Callejas, S., Benguria, A., Moreno, A., Alonso, J., Palmero, I., 2010.
Regulation of the microRNA processor DGCR8 by the tumor suppressor ING1. Cancer
Res. 70, 1866-1874.
Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W., Chen, J., et al., 2011. Up-regulation of miR-
21 mediates resistance to Trastuzumab therapy for breast cancer. J. Biol. Chem. 286,
19127-19137.
Gong, W., Russell, M., Suzuki, K., Riabowol, K., 2006. Subcellular targeting of p33 ING1b by
phosphorylation-dependent 14-3-3 binding regulates p21 WAF1 expression. Mol. Cell.
Biol. 26, 2947-2954.
Goodfellow, H., Krejcí, A., Moshkin, Y., Verrijzer, C.P., Karch, F., Bray, S.J., 2007. Gene-specific
targeting of the histone chaperone asf1 to mediate silencing. Develop Cell 13, 593-600.
Goodison, S., Yuan, J., Sloan, D., Kim, R., Li, C., Popescu, N.C., et al., 2005. The RhoGAP
protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res.
65, 6042-6053.
Gopal, Y.N.V., Chanchorn, E., Van Dyke, M.W., 2009. Parthenolide promotes the ubiquitina-
tion of MDM2 and activates p53 cellular functions. Mol. Cancer Ther. 8, 552-562.
Gordon, K.J., Dong, M., Chislock, E.M., Fields, T.A., Blobe, G.C., 2008. Loss of type III
transforming growth factor beta receptor expression increases motility and invasiveness
associated with epithelial to mesenchymal transition during pancreatic cancer progres-
sion. Carcinogenesis 29, 252-262.
Gordon, M., El-Kalla, M., Baksh, S., 2012. RASSF1 polymorphisms in cancer. Mol. Biol. Int.
2012, 365213.
Gottesman, M.M., 2002. Mechanisms of cancer drug resistance. Ann. Rev. Med. 63, 615-627.
Graham, R.A., Morrison, G.E., Chang, I., Jorga, K., Hop, C., Shin, Y., et al. 2010.
Bioavailablility of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacoki-
netic (PK) study in healthy female subjects. J. Clin. Oncol. 28, e13009.
Gramling, M.W., Eischen, C.M., 2012. Suppression of Ras/Mapk pathway signaling inhibits
Myc-induced lymphomagenesis. Cell Death Differ. 19, 1220-1227.
Granovsky, A.E., Clark, M.C., McElheny, D., Heil, G., Hong, J., Liu, X., et al., 2009. Raf
kinase inhibitory protein function is regulated via a flexible pocket and novel phosphoryl-
ation-dependent mechanism. Mol. Cell. Biol. 29, 1306-1320.
Gregory, R.I., Yan, K.P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., et al., 2004.
The microprocessor complex mediates the genesis of microRNAs. Nature 432, 235-240.
Grewal, S.I., Elgin, S.C., 2007. Transcription and RNA interference in the formation of
heterochromatin. Nature 447, 399-406.
Grigorian, M., Tulchinsky, E., Burrone, O., Tarabykina, S., Georgiev, G., Lukanidin, E.,
1994. Modulation of Mts1 expression in mouse and human normal and tumour cells.
Electrophoresis 15, 3-4.
Griner, E.M., Kazanietz, M.G., 2007. Protein kinase C and other diacylglyerol effector in can-
cer. Nature Rev. 7, 281-294.